Acide étacrynique : interactions médicamenteuses

Acide étacrynique (Edecrin), diurétique de l'anse, présente 364 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 51 de niveau majeur, 248 de niveau modéré, 64 de niveau mineur et 1 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (51)

  • Acétazolamideinhibiteur de l'anhydrase carboniqueMajeure

    Like other diuretics it may precipitate hepatic coma and death. (notice Acide étacrynique, Mises en garde)

  • AmikacineaminosideMajeure

    Avoid concomitant use of ARIKAYCE with ethacrynic acid, furosemide, urea, or intravenous mannitol. (notice Amikacine, Interactions médicamenteuses)

  • Amiloridediurétique épargneur de potassiumMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Aténolol et chlortalidonebêtabloquantMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Bicarbonate de sodiumantiacideMajeure

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (notice Bicarbonate de sodium, Contre-indications)

  • CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Bumétanidediurétique de l'anseMajeure

    Like other diuretics it may precipitate hepatic coma and death. (notice Acide étacrynique, Mises en garde)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Chlorothiazidediurétique thiazidiqueMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Chlortalidonediurétique thiazidiqueMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (notice Choriogonadotropine alfa, Mises en garde)

  • CiclosporineimmunosuppresseurMajeure

    Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (notice Ciclosporine, Interactions médicamenteuses)

  • Citrate de potassiumsupplément de potassiumMajeure

    The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (notice Citrate de potassium, Interactions médicamenteuses)

  • ClozapineantipsychotiqueMajeure

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (notice Clozapine, Mise en garde encadrée)

  • Digoxineglycoside digitaliqueMajeure

    These generally have fallen into two categories: (1) patients with severe myocardial disease who have been receiving digitalis and presumably developed acute hypokalemia with fatal arrhythmia; (2) patients with severely decompensated hepatic cirrhosis with ascites, with or without accompanying encephalopathy, who were in electrolyte imbalance and died because… (notice Acide étacrynique, Mises en garde)

  • DofétilideantiarythmiqueMajeure

    In the DIAMOND trials, 1252 patients were treated with dofetilide and diuretics concomitantly, of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. (notice Dofétilide, Interactions médicamenteuses)

  • Dropéridolantagoniste de la dopamineMajeure

    Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (notice Dropéridol, Mise en garde encadrée)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Énalaprilateinhibiteur de l'enzyme de conversion (IEC)Majeure

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (notice Énalaprilate, Mises en garde)

  • Éplérénoneantagoniste de l'aldostéroneMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Eptifibatideantiagrégant plaquettaireMajeure

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (notice Eptifibatide, Contre-indications)

  • Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (notice Follitropine, Mises en garde et précautions)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Furosémidediurétique de l'anseMajeure

    Like other diuretics it may precipitate hepatic coma and death. (notice Acide étacrynique, Mises en garde)

  • GentamicineaminosideMajeure

    The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (notice Gentamicine, Mise en garde encadrée)

  • Hydrochlorothiazidediurétique thiazidiqueMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Indapamidediurétique thiazidiqueMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Avoid diuretics or laxatives in patients with diarrhea. (notice Irinotécan, Mises en garde et précautions)

  • Itraconazoleantifongique azoléMajeure

    Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (notice Itraconazole, Interactions médicamenteuses)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Métolazonediurétique thiazidiqueMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • MinoxidilvasodilatateurMajeure

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (notice Minoxidil, Mise en garde encadrée)

  • NéomycineaminosideMajeure

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (notice Néomycine, Mise en garde encadrée)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Quinaprilinhibiteur de l'enzyme de conversion (IEC)Majeure

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (notice Quinapril, Mises en garde)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Spironolactoneantagoniste de l'aldostéroneMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Tadalafilinhibiteur de la PDE5Majeure

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (notice Tadalafil, Mises en garde et précautions)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • TobramycineaminosideMajeure

    TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (notice Tobramycine, Interactions médicamenteuses)

  • Torasémidediurétique de l'anseMajeure

    Like other diuretics it may precipitate hepatic coma and death. (notice Acide étacrynique, Mises en garde)

  • Triamtérènediurétique épargneur de potassiumMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumMajeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

  • Trioxyde d'arsenicmédicament allongeant l'intervalle QTMajeure

    The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (notice Trioxyde d'arsenic, Mises en garde et précautions)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Majeure

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (notice Acide étacrynique, Contre-indications)

Interactions modérées (248)

  • AcébutololbêtabloquantModérée

    Although β-blockers should be avoided in overt cardiac failure, acebutolol can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. (notice Acébutolol, Mises en garde)

  • Acide méfénamiqueAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Acide zolédroniquebisphosphonateModérée

    Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (notice Acide zolédronique, Mises en garde et précautions)

  • AdrénalinesympathomimétiqueModérée

    …Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline… (notice Adrénaline, Interactions médicamenteuses)

  • AlfuzosinealphabloquantModérée

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (notice Alfuzosine, Mises en garde et précautions)

  • AliskirèneantihypertenseurModérée

    Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (notice Aliskirène, Mises en garde et précautions)

  • Allopurinolinhibiteur de la xanthine oxydaseModérée

    Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (notice Allopurinol, Mises en garde et précautions)

  • Alogliptine et metformineinhibiteur de la DPP-4Modérée

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (notice Alogliptine et metformine, Interactions médicamenteuses)

  • Amfépramonestimulant du SNCModérée

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (notice Amfépramone, Interactions médicamenteuses)

  • AmiodaroneantiarythmiqueModérée

    Give special attention to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics and laxatives. (notice Amiodarone, Mises en garde et précautions)

  • Amlodipine et bénazéprilinhibiteur calcique dihydropyridiniqueModérée

    Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (notice Amlodipine et bénazépril, Mises en garde et précautions)

  • Amlodipine et olmésartaninhibiteur calcique dihydropyridiniqueModérée

    In patients with an activated renin-angiotensin system, such as volume and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil . (notice Amlodipine et olmésartan, Mises en garde et précautions)

  • Amlodipine et valsartaninhibiteur calcique dihydropyridiniqueModérée

    In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur in patients receiving angiotensin receptor blockers. (notice Amlodipine et valsartan, Mises en garde et précautions)

  • ApixabananticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • Arformotérolagoniste bêta-adrénergiqueModérée

    Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (notice Arformotérol, Interactions médicamenteuses)

  • ArgatrobananticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • AripiprazoleantipsychotiqueModérée

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (notice Aripiprazole, Interactions médicamenteuses)

  • Armodafinilstimulant du SNCModérée

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (notice Armodafinil, Mises en garde et précautions)

  • AsénapineantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (notice Asénapine, Mises en garde et précautions)

  • AspirineAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Aspirine et dipyridamoleantiagrégant plaquettaireModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • AténololbêtabloquantModérée

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (notice Aténolol, Mises en garde)

  • Atomoxétineinhibiteur de la recapture de la noradrénalineModérée

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (notice Atomoxétine, Interactions médicamenteuses)

  • Avanafilinhibiteur de la PDE5Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Azilsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with azilsartan medoxomil. (notice Azilsartan, Mises en garde et précautions)

  • Belladone et opiumopioïdeModérée

    Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Belladone et opium, Interactions médicamenteuses)

  • Bénazéprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (notice Bénazépril, Mises en garde et précautions)

  • Benzfétaminestimulant du SNCModérée

    Amphetamines may decrease the hypotensive effect of antihypertensives. (notice Benzfétamine, Interactions médicamenteuses)

  • Bexagliflozineinhibiteur du SGLT2Modérée

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (notice Bexagliflozine, Mises en garde et précautions)

  • BisoprololbêtabloquantModérée

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (notice Bisoprolol, Mises en garde)

  • BivalirudineanticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • BortézomibModérée

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (notice Bortézomib, Mises en garde et précautions)

  • BrexpiprazoleantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (notice Brexpiprazole, Mises en garde et précautions)

  • Brimonidineagoniste alpha-adrénergiqueModérée

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (notice Brimonidine, Interactions médicamenteuses)

  • Brimonidine et timololagoniste alpha-adrénergiqueModérée

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (notice Brimonidine et timolol, Interactions médicamenteuses)

  • Bromocriptineagoniste de la dopamineModérée

    Use caution in patients taking antihypertensive medications. (notice Bromocriptine, Mises en garde et précautions)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (notice Bromphéniramine, pseudoéphédrine et dextrométhorphane, Interactions médicamenteuses)

  • Budésonide et formotérolcorticoïdeModérée

    Diuretics: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

  • BuprénorphineopioïdeModérée

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Buprénorphine, Interactions médicamenteuses)

  • Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Buprénorphine et naloxone, Interactions médicamenteuses)

  • In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Butalbital, paracétamol, caféine et codéine, Interactions médicamenteuses)

  • Canagliflozineinhibiteur du SGLT2Modérée

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (notice Canagliflozine, Mises en garde et précautions)

  • Candésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (notice Candésartan, Mises en garde et précautions)

  • Captoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (notice Captopril, Mises en garde)

  • CarbamazépineanticonvulsivantModérée

    Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (notice Carbamazépine, Mises en garde et précautions)

  • CarbidopaModérée

    Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (notice Carbidopa, Interactions médicamenteuses)

  • Carbidopa et lévodopamédicament dopaminergiqueModérée

    Antihypertensive drugs: May cause symptomatic postural hypotension. (notice Carbidopa et lévodopa, Interactions médicamenteuses)

  • Carbidopa, lévodopa et entacaponemédicament dopaminergiqueModérée

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (notice Carbidopa, lévodopa et entacapone, Interactions médicamenteuses)

  • CariprazineantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (notice Cariprazine, Mises en garde et précautions)

  • CarvédilolbêtabloquantModérée

    If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (notice Carvédilol, Mises en garde et précautions)

  • CéfaclorcéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CéfadroxilcéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CéfalexinecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CéfazolinecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CefdinircéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CéfépimecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CéfiximecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CéfotaximecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CéfotétancéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CéfoxitinecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CefpodoximecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CefprozilcéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CeftarolinecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CeftazidimecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CeftriaxonecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CéfuroximecéphalosporineModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • CélécoxibAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • ChlorpromazineantipsychotiqueModérée

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (notice Chlorpromazine, Précautions)

  • Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (notice Chlorure de calcium, Interactions médicamenteuses)

  • CitalopramISRSModérée

    Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (notice Citalopram, Mises en garde et précautions)

  • ClofarabineantimétaboliteModérée

    Consider use of diuretics and/or albumin. (notice Clofarabine, Mises en garde et précautions)

  • CodéineopioïdeModérée

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Codéine, Interactions médicamenteuses)

  • Colestyraminechélateur des acides biliairesModérée

    Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (notice Colestyramine, Interactions médicamenteuses)

  • CyclobenzaprinemyorelaxantModérée

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (notice Cyclobenzaprine, Interactions médicamenteuses)

  • CyclophosphamideimmunosuppresseurModérée

    …inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity ● Amiodarone… (notice Cyclophosphamide, Interactions médicamenteuses)

  • Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (notice Cyclosilicate de zirconium sodique, Mises en garde et précautions)

  • DabigatrananticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • Dapagliflozineinhibiteur du SGLT2Modérée

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (notice Dapagliflozine, Mises en garde et précautions)

  • Dapagliflozine et metformineinhibiteur du SGLT2Modérée

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (notice Dapagliflozine et metformine, Mises en garde et précautions)

  • Désipramineantidépresseur tricycliqueModérée

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (notice Désipramine, Mises en garde)

  • DesmopressineModérée

    …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (notice Desmopressine, Interactions médicamenteuses)

  • DesvenlafaxineIRSNaModérée

    Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (notice Desvenlafaxine, Mises en garde et précautions)

  • Dexlansoprazoleinhibiteur de la pompe à protons (IPP)Modérée

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (notice Dexlansoprazole, Mises en garde et précautions)

  • Dexméthylphénidatestimulant du SNCModérée

    • Antihypertensive Drugs: Monitor blood pressure. (notice Dexméthylphénidate, Interactions médicamenteuses)

  • DiazoxideModérée

    The concomitant administration of thiazides or other diuretics may potentiate the hyperglycemic and hyperuricemic effects of PROGLYCEM. (notice Diazoxide, Interactions médicamenteuses)

  • DiclofénacAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Diclofénamideinhibiteur de l'anhydrase carboniqueModérée

    Drugs that Cause Hypokalemia The risk of hypokalemia is greater with coadministration of KEVEYIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline) [see Warnings and Precautions (5.3) ] . (notice Diclofénamide, Interactions médicamenteuses)

  • DiflunisalAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Doxercalciférolanalogue de la vitamine DModérée

    Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (notice Doxercalciférol, Mises en garde et précautions)

  • Drospirénone et éthinylestradiolcontraceptif oralModérée

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (notice Drospirénone et éthinylestradiol, Mises en garde et précautions)

  • DuloxétineIRSNaModérée

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (notice Duloxétine, Mises en garde et précautions)

  • ÉdoxabananticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • Empagliflozineinhibiteur du SGLT2Modérée

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (notice Empagliflozine, Mises en garde et précautions)

  • Empagliflozine et metformineinhibiteur du SGLT2Modérée

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (notice Empagliflozine et metformine, Mises en garde et précautions)

  • Énalaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (notice Énalapril, Mises en garde et précautions)

  • ÉnoxaparineanticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Époprosténolanalogue de prostaglandineModérée

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (notice Époprosténol, Interactions médicamenteuses)

  • EscitalopramISRSModérée

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (notice Escitalopram, Mises en garde et précautions)

  • EsmololbêtabloquantModérée

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (notice Esmolol, Interactions médicamenteuses)

  • Ésoméprazoleinhibiteur de la pompe à protons (IPP)Modérée

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (notice Ésoméprazole, Mises en garde et précautions)

  • ÉtodolacAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • FénoprofèneAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • FentanylopioïdeModérée

    …treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (notice Fentanyl, Mises en garde et précautions)

  • Fluconazoleantifongique azoléModérée

    An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. (notice Fluconazole, Interactions médicamenteuses)

  • FludrocortisonecorticoïdeModérée

    Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

  • FluoxétineISRSModérée

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (notice Fluoxétine, Mises en garde et précautions)

  • FlurbiprofèneAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Fluticasone et salmétérolcorticoïdeModérée

    Diuretics: Use with caution. (notice Fluticasone et salmétérol, Interactions médicamenteuses)

  • FluvoxamineISRSModérée

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (notice Fluvoxamine, Mises en garde et précautions)

  • FondaparinuxanticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • Formotérolagoniste bêta-adrénergiqueModérée

    • Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (notice Formotérol, Interactions médicamenteuses)

  • FoscarnetantiviralModérée

    When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (notice Foscarnet, Interactions médicamenteuses)

  • Fosinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Symptomatic hypotension is most likely to occur in patients who have been volume- and/or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (notice Fosinopril, Mises en garde)

  • Glimépiridesulfamide hypoglycémiantModérée

    …danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline),… (notice Glimépiride, Interactions médicamenteuses)

  • Glipizidesulfamide hypoglycémiantModérée

    …may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic… (notice Glipizide, Interactions médicamenteuses)

  • HalopéridolantipsychotiqueModérée

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (notice Halopéridol, Interactions médicamenteuses)

  • HéparineanticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • HydrocodoneopioïdeModérée

    Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Hydrocodone, Interactions médicamenteuses)

  • Diuretics : Hydrocodone may reduce the efficacy of diuretics. (notice Hydrocodone et chlorphénamine, Interactions médicamenteuses)

  • Diuretics : Hydrocodone may reduce the efficacy of diuretics. (notice Hydrocodone et homatropine, Interactions médicamenteuses)

  • In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Hydrocodone et paracétamol, Interactions médicamenteuses)

  • HydromorphoneopioïdeModérée

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Hydromorphone, Interactions médicamenteuses)

  • IbuprofèneAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • IlopéridoneantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (notice Ilopéridone, Mises en garde et précautions)

  • Imipramineantidépresseur tricycliqueModérée

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (notice Imipramine, Mises en garde)

  • IndométacineAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Insuline asparteinsulineModérée

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (notice Insuline asparte, Interactions médicamenteuses)

  • Insuline dégludecinsulineModérée

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (notice Insuline dégludec, Interactions médicamenteuses)

  • Insuline détémirinsulineModérée

    Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (notice Insuline détémir, Interactions médicamenteuses)

  • Insuline glargineinsulineModérée

    Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (notice Insuline glargine, Interactions médicamenteuses)

  • Insuline lisproinsulineModérée

    Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (notice Insuline lispro, Interactions médicamenteuses)

  • Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (notice Iodure de potassium, Interactions médicamenteuses)

  • Ipratropium et salbutamolanticholinergiqueModérée

    Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (notice Ipratropium et salbutamol, Interactions médicamenteuses)

  • Irbésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Hypotension in Volume or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with AVAPRO. (notice Irbésartan, Mises en garde et précautions)

  • Kétoconazoleantifongique azoléModérée

    Diuretics eplerenone The potential increase in plasma concentrations of eplerenone when coadministered with ketoconazole tablets may increase the risk of hyperkalemia and hypotension. (notice Kétoconazole, Interactions médicamenteuses)

  • KétoprofèneAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • KétorolacAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Lansoprazoleinhibiteur de la pompe à protons (IPP)Modérée

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (notice Lansoprazole, Mises en garde et précautions)

  • LévomilnacipranIRSNaModérée

    Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (notice Lévomilnacipran, Mises en garde et précautions)

  • LévorphanolopioïdeModérée

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Lévorphanol, Interactions médicamenteuses)

  • Lévosalbutamolagoniste bêta-adrénergiqueModérée

    Diuretics The ECG changes or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (notice Lévosalbutamol, Interactions médicamenteuses)

  • LinézolideantibiotiqueModérée

    Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (notice Linézolide, Mises en garde et précautions)

  • Lisinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (notice Lisinopril, Mises en garde et précautions)

  • Lithiummédicament sérotoninergiqueModérée

    Lithium generally should not be given with diuretics (see PRECAUTIONS, Drug Interactions ). (notice Acide étacrynique, Mises en garde)

  • Losartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (notice Losartan, Mises en garde et précautions)

  • LumatépéroneantipsychotiqueModérée

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (notice Lumatépérone, Mises en garde et précautions)

  • LurasidoneantipsychotiqueModérée

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (notice Lurasidone, Mises en garde et précautions)

  • MécamylamineantihypertenseurModérée

    The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (notice Mécamylamine, Interactions médicamenteuses)

  • MéloxicamAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • MéthadoneopioïdeModérée

    Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (notice Méthadone, Mises en garde et précautions)

  • Méthylphénidatestimulant du SNCModérée

    Antihypertensive Drugs: Monitor blood pressure. (notice Méthylphénidate, Interactions médicamenteuses)

  • MétoprololbêtabloquantModérée

    If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of Metoprolol Tartrate Tablets [see Dosage and Administration (2) ]. (notice Métoprolol, Mises en garde et précautions)

  • MilnacipranIRSNaModérée

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (notice Milnacipran, Mises en garde et précautions)

  • MirtazapineantidépresseurModérée

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (notice Mirtazapine, Mises en garde et précautions)

  • Modafinilstimulant du SNCModérée

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (notice Modafinil, Mises en garde et précautions)

  • Moexiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Symptomatic hypotension is most likely to occur in patients who have been salt- and volume- depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (notice Moexipril, Mises en garde)

  • MorphineopioïdeModérée

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Morphine, Interactions médicamenteuses)

  • NabumétoneAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • NadololbêtabloquantModérée

    Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (notice Nadolol, Mises en garde)

  • NalbuphineopioïdeModérée

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Nalbuphine, Interactions médicamenteuses)

  • NaproxèneAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • NiacineModérée

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (notice Niacine, Interactions médicamenteuses)

  • Nifédipineinhibiteur calcique dihydropyridiniqueModérée

    Other Diuretics, PDE5 inhibitors, alpha-methyldopa: Nifedipine may increase the blood pressure lowering effect of these concomitantly administered agents. (notice Nifédipine, Interactions médicamenteuses)

  • Nimodipineinhibiteur calcique dihydropyridiniqueModérée

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (notice Nimodipine, Interactions médicamenteuses)

  • OlanzapineantipsychotiqueModérée

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (notice Olanzapine, Mises en garde et précautions)

  • Olanzapine et fluoxétineantipsychotiqueModérée

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (notice Olanzapine et fluoxétine, Mises en garde et précautions)

  • OlicéridineopioïdeModérée

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Olicéridine, Interactions médicamenteuses)

  • Olmésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin-aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Benicar. (notice Olmésartan, Mises en garde et précautions)

  • Oméprazoleinhibiteur de la pompe à protons (IPP)Modérée

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (notice Oméprazole, Mises en garde et précautions)

  • Oméprazole et bicarbonate de sodiuminhibiteur de la pompe à protons (IPP)Modérée

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (notice Oméprazole et bicarbonate de sodium, Mises en garde et précautions)

  • In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • OxaprozineAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • OxycodoneopioïdeModérée

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Oxycodone, Interactions médicamenteuses)

  • Oxycodone et paracétamolopioïdeModérée

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Oxycodone et paracétamol, Interactions médicamenteuses)

  • OxymorphoneopioïdeModérée

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Oxymorphone, Interactions médicamenteuses)

  • PalipéridoneantipsychotiqueModérée

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (notice Palipéridone, Mises en garde et précautions)

  • Pantoprazoleinhibiteur de la pompe à protons (IPP)Modérée

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (notice Pantoprazole, Mises en garde et précautions)

  • Paracétamol et codéineopioïdeModérée

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Paracétamol et codéine, Interactions médicamenteuses)

  • In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • Paricalcitolanalogue de la vitamine DModérée

    The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (notice Paricalcitol, Mises en garde et précautions)

  • ParoxétineISRSModérée

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (notice Paroxétine, Mises en garde et précautions)

  • PazopanibModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Pentazocine et naloxoneopioïdeModérée

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Pentazocine et naloxone, Interactions médicamenteuses)

  • PentoxifyllineméthylxanthineModérée

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (notice Pentoxifylline, Interactions médicamenteuses)

  • Périndoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Symptomatic hypotension is most likely to occur in patients who have been volume or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting [see Dosage and Administration (2.1) ] . (notice Périndopril, Mises en garde et précautions)

  • PéthidineopioïdeModérée

    Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Péthidine, Interactions médicamenteuses)

  • PhénelzineIMAOModérée

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (notice Phénelzine, Mises en garde)

  • Phentermine et topiramatestimulant du SNCModérée

    In addition, when phentermine and topiramate extended-release capsules are used in conjunction with nonpotassium sparing diuretics this may further potentiate potassium-wasting. (notice Phentermine et topiramate, Mises en garde et précautions)

  • PindololbêtabloquantModérée

    Although beta-blockers should be avoided in overt congestive heart failure, if necessary, pindolol tablets can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (notice Pindolol, Mises en garde)

  • Pioglitazone et glimépiridethiazolidinedioneModérée

    …danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline),… (notice Pioglitazone et glimépiride, Interactions médicamenteuses)

  • PiroxicamAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • PlazomicineaminosideModérée

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (notice Acide étacrynique, Interactions médicamenteuses)

  • PrazosinealphabloquantModérée

    Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (notice Prazosine, Mises en garde)

  • ProchlorpérazineantipsychotiqueModérée

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (notice Prochlorpérazine, Précautions)

  • Prométhazine et codéineopioïdeModérée

    Diuretics : Codeine may reduce the efficacy of diuretics. (notice Prométhazine et codéine, Interactions médicamenteuses)

  • QuétiapineantipsychotiqueModérée

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (notice Quétiapine, Mises en garde et précautions)

  • QuinidineantiarythmiqueModérée

    Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine. (notice Quinidine, Interactions médicamenteuses)

  • Rabéprazoleinhibiteur de la pompe à protons (IPP)Modérée

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (notice Rabéprazole, Mises en garde et précautions)

  • Ramiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (notice Ramipril, Mises en garde et précautions)

  • RiociguatvasodilatateurModérée

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (notice Riociguat, Mises en garde et précautions)

  • RispéridoneantipsychotiqueModérée

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (notice Rispéridone, Mises en garde et précautions)

  • RivaroxabananticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • Sacubitril et valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. (notice Sacubitril et valsartan, Mises en garde et précautions)

  • Salbutamolagoniste bêta-adrénergiqueModérée

    Diuretics: Use with caution. (notice Salbutamol, Interactions médicamenteuses)

  • Salmétérolagoniste bêta-adrénergiqueModérée

    • Diuretics: Use with caution. (notice Salmétérol, Interactions médicamenteuses)

  • SalsalateAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • SertralineISRSModérée

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (notice Sertraline, Mises en garde et précautions)

  • Sildénafilinhibiteur de la PDE5Modérée

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

  • SilodosinealphabloquantModérée

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (notice Silodosine, Mises en garde et précautions)

  • SorafénibModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • SotalolbêtabloquantModérée

    Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (notice Sotalol, Mises en garde et précautions)

  • Drug Interactions In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. (notice Sulfaméthoxazole et triméthoprime, Interactions médicamenteuses)

  • SulindacAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • SunitinibModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Suxaméthoniumbloquant neuromusculaireModérée

    Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (notice Suxaméthonium, Mises en garde et précautions)

  • TacrolimusimmunosuppresseurModérée

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (notice Tacrolimus, Mises en garde et précautions)

  • TapentadolopioïdeModérée

    …use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Tapentadol, Interactions médicamenteuses)

  • Telmisartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Hypotension In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan tablets. (notice Telmisartan, Mises en garde et précautions)

  • Telmisartan et amlodipineantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (notice Telmisartan et amlodipine, Mises en garde et précautions)

  • TérazosinealphabloquantModérée

    Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (notice Térazosine, Mises en garde et précautions)

  • Terbutalineagoniste bêta-adrénergiqueModérée

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (notice Terbutaline, Précautions)

  • TestostéroneandrogèneModérée

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (notice Testostérone, Mises en garde et précautions)

  • TolmétineAINSModérée

    In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (notice Acide étacrynique, Interactions médicamenteuses)

  • TolvaptanModérée

    Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (notice Tolvaptan, Mises en garde et précautions)

  • Torémifènemodulateur sélectif des récepteurs aux estrogènesModérée

    Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (notice Torémifène, Interactions médicamenteuses)

  • TramadolopioïdeModérée

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Tramadol, Interactions médicamenteuses)

  • Tramadol et paracétamolopioïdeModérée

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (notice Tramadol et paracétamol, Interactions médicamenteuses)

  • Trandolaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Symptomatic hypotension is most likely to occur in patients who have been salt- or volume-depleted as a result of prolonged treatment with diuretics, dietary salt restriction, dialysis, diarrhea, or vomiting. (notice Trandolapril, Mises en garde)

  • TrazodoneantidépresseurModérée

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (notice Trazodone, Mises en garde et précautions)

  • TrifluopérazineantipsychotiqueModérée

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (notice Trifluopérazine, Précautions)

  • Trinitrinedérivé nitréModérée

    Antihypertensives: Possible additive hypotensive effects. (notice Trinitrine, Interactions médicamenteuses)

  • Uméclidinium et vilantérolanticholinergiqueModérée

    • Diuretics: Use with caution. (notice Uméclidinium et vilantérol, Interactions médicamenteuses)

  • Valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. (notice Valsartan, Mises en garde et précautions)

  • Vardénafilinhibiteur de la PDE5Modérée

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (notice Vardénafil, Interactions médicamenteuses)

  • VenlafaxineIRSNaModérée

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (notice Venlafaxine, Mises en garde et précautions)

  • Vérapamilinhibiteur calciqueModérée

    Control patients with milder ventricular dysfunction, if possible, with optimum doses of digitalis and/or diuretics before verapamil treatment is started [see Drug Interactions ( 7.5 )] . (notice Vérapamil, Mises en garde et précautions)

  • VilazodoneISRSModérée

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (notice Vilazodone, Mises en garde et précautions)

  • VortioxétineantidépresseurModérée

    Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (notice Vortioxétine, Mises en garde et précautions)

  • WarfarineanticoagulantModérée

    A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (notice Acide étacrynique, Interactions médicamenteuses)

  • ZiprasidoneantipsychotiqueModérée

    Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (notice Ziprasidone, Mises en garde et précautions)

Mentions mineures (64)

  • AcarboseantidiabétiqueMineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (notice Acarbose, Interactions médicamenteuses)

  • Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (notice Ambrisentan, Mises en garde et précautions)

  • Azélastine et fluticasoneantihistaminiqueMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • BéclométasonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • BétaméthasonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • BétaxololbêtabloquantMineure

    In hypertensive patients who have congestive heart failure controlled by digitalis and diuretics, beta-blockers should be administered cautiously. (notice Bétaxolol, Mises en garde)

  • Bosentaninducteur du CYP3A4Mineure

    Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (notice Bosentan, Mises en garde et précautions)

  • BudésonidecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • ButorphanolopioïdeMineure

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (notice Butorphanol, Mises en garde)

  • CiclésonidecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • ClobétasolcorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (notice Corticotropine, Interactions médicamenteuses)

  • DasatinibMineure

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

  • DéflazacortcorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • Désogestrel et éthinylestradiolcontraceptif oralMineure

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (notice Désogestrel et éthinylestradiol, Mises en garde)

  • DésonidecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • DexaméthasonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • Dexamfétaminestimulant du SNCMineure

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (notice Dexamfétamine, Interactions médicamenteuses)

  • DocétaxelMineure

    Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (notice Docétaxel, Mises en garde et précautions)

  • DronédaroneantiarythmiqueMineure

    Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. (notice Dronédarone, Mises en garde et précautions)

  • ÉphédrinesympathomimétiqueMineure

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (notice Éphédrine, Interactions médicamenteuses)

  • In addition to discontinuation of the drug, diuretic therapy may be required. (notice Estrogènes estérifiés et méthyltestostérone, Mises en garde)

  • Finastérideinhibiteur de la 5-alpha-réductaseMineure

    …clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (notice Finastéride, Interactions médicamenteuses)

  • FlécaïnideantiarythmiqueMineure

    Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (notice Flécaïnide, Interactions médicamenteuses)

  • FlunisolidecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • FluocinonidecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • FluticasonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • Glibenclamidesulfamide hypoglycémiantMineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glibenclamide, Interactions médicamenteuses)

  • Glibenclamide et metforminesulfamide hypoglycémiantMineure

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Glibenclamide et metformine, Interactions médicamenteuses)

  • Glipizide et metforminesulfamide hypoglycémiantMineure

    These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Glipizide et metformine, Précautions)

  • Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (notice Gluconate de calcium, Interactions médicamenteuses)

  • HalobétasolcorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • HydralazinevasodilatateurMineure

    When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (notice Hydralazine, Interactions médicamenteuses)

  • HydrocortisonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • IcatibantMineure

    ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (notice Icatibant, Interactions médicamenteuses)

  • Imatinibinhibiteur du CYP3A4Mineure

    Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (notice Imatinib, Mises en garde et précautions)

  • Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (notice Insuline rapide (humaine), Interactions médicamenteuses)

  • Isradipineinhibiteur calcique dihydropyridiniqueMineure

    In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (notice Isradipine, Interactions médicamenteuses)

  • Linagliptine et metformineinhibiteur de la DPP-4Mineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Linagliptine et metformine, Interactions médicamenteuses)

  • MacitentanMineure

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (notice Macitentan, Mises en garde et précautions)

  • MagnésiumVitamines et minérauxMineure

    L'utilisation à long terme des diurétiques de l'anse et des diurétiques thiazidiques augmente la perte de magnésium dans les urines. (NIH Office of Dietary Supplements, Magnesium)

  • MetforminebiguanideMineure

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Metformine, Interactions médicamenteuses)

  • MéthyldopaantihypertenseurMineure

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (notice Méthyldopa, Interactions médicamenteuses)

  • MéthylprednisolonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • MéthyltestostéroneandrogèneMineure

    In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

  • MexilétineantiarythmiqueMineure

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (notice Mexilétine, Interactions médicamenteuses)

  • MométasonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • Nisoldipineinhibiteur calcique dihydropyridiniqueMineure

    The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (notice Nisoldipine, Interactions médicamenteuses)

  • Nitroprussiate de sodiumvasodilatateurMineure

    Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (notice Nitroprussiate de sodium, Mises en garde)

  • Nortriptylineantidépresseur tricycliqueMineure

    The antihypertensive action of guanethidine and similar agents may be blocked. (notice Nortriptyline, Mises en garde)

  • Olopatadine et mométasoneantihistaminiqueMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • Pénicilline Gantibiotique de la famille des pénicillinesMineure

    These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid. (notice Pénicilline G, Interactions médicamenteuses)

  • Pioglitazone et metforminethiazolidinedioneMineure

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Pioglitazone et metformine, Interactions médicamenteuses)

  • Pipéracilline et tazobactamantibiotique de la famille des pénicillinesMineure

    Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics. (notice Pipéracilline et tazobactam, Mises en garde et précautions)

  • PotassiumVitamines et minérauxMineure

    Les diurétiques de l'anse et les diurétiques thiazidiques augmentent la perte de potassium ; une supplémentation est parfois prescrite en même temps qu'eux. (NIH Office of Dietary Supplements, Potassium)

  • PrednisolonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • PrednisonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

  • Protriptylineantidépresseur tricycliqueMineure

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (notice Protriptyline, Mises en garde)

  • RépaglinideglinideMineure

    Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (notice Répaglinide, Interactions médicamenteuses)

  • Saxagliptine et metformineinhibiteur de la DPP-4Mineure

    These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (notice Saxagliptine et metformine, Interactions médicamenteuses)

  • Sitagliptine et metformineinhibiteur de la DPP-4Mineure

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (notice Sitagliptine et metformine, Interactions médicamenteuses)

  • SulfadiazinesulfamideMineure

    Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (notice Sulfadiazine, Interactions médicamenteuses)

  • TerbinafineantifongiqueMineure

    There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (notice Terbinafine, Interactions médicamenteuses)

  • TriamcinolonecorticoïdeMineure

    Care should also be exercised in patients receiving potassium-depleting steroids. (notice Acide étacrynique, Mises en garde)

Aucune interaction significative signalée (1)

  • Acide pamidroniquebisphosphonateAucune interaction

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (notice Acide pamidronique, Interactions médicamenteuses)

Vérifiez Acide étacrynique avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.